Cronos Stock Price: 52-Week Lows Continue for This Cannabis Stock

Here’s why Cronos stock remains a high-risk bet for long-term investors right now.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Most Canadian marijuana producers have trailed the broader markets in 2021. This includes shares of cannabis heavyweight Cronos Group (TSX:CRON)(NASDAQ:CRON), which are down 46% in the past year and 81% below all-time highs.

Despite the significant pullback, Cronos Group is valued at a market cap of $2.14 billion, making it one of the largest cannabis companies in Canada. While Cronos has burnt investor wealth in the last three years, the stock is still up 261% in the last five years. Let’s see if you need to add CRON stock to your portfolio right now or if it remains a high-risk bet at current levels.

Cronos stock is wrestling with regulatory issues

In the last month, Cronos stock has fallen over 10% after the company announced the delay of the filing of its quarterly report. The marijuana heavyweight explained it needs time to analyze the impairment charges the company will report for its CBD, or cannabidiol, business. Cronos confirmed impairment charges will amount to at least $220 million in Q3 of 2021.

Cronos acquired Redwood Holding for $300 million two years back to gain access to its lineup of CBD-infused oils, gummies, and other products. But in Q2 of 2021, Cronos reported a goodwill impairment charge of $40 million, which indicates the acquisition was overvalued.

Investors initially expected the delay in filings to be tied to an acquisition announcement by tobacco company Altria. In 2019, Altria invested $1.9 billion in Cronos for a 45% stake. But over the last two years, Altria has written down the value of the acquisition multiple times.

Several analysts remain bearish on Cronos stock. According to a report from The Fly, Barclays analyst Gaurav Jain initiated coverage on Cronos stock with a price target of US$5.5 and an “Underweight” rating. Jain emphasized that Canadian cannabis companies are unable to gain a controlling stake in multi-state operators south of the border, as marijuana is still illegal at the federal level. The U.S.-based cannabis companies have stronger fundamentals and are racing towards profitability compared to their Canadian counterparts who continue to grapple with widening losses and poor execution.

What’s next for CRON stock?

Analysts tracking Cronos expect the company to increase sales by 84.8% year over year to $86.4 million in 2021 and by 80% to $155 million in 2022. However, the company’s loss per share is forecast to widen from $0.21 in 2020 to $0.36 in 2022. We can see that despite the decline in CRON stock this year, it’s still trading at a forward price-to-2022-sales multiple of 13.8, which is sky-high compared to marijuana companies in the U.S.

Cronos ended Q2 with a cash balance of $1.1 billion, which provides it with enough room to improve profit margins going forward. The backing of Altria Group also provides Cronos with enough flexibility in the medium term. But will Altria continue to pump in money into a company that is wrestling with regulatory concerns, significant losses, and more?

CRON stock remains a high-risk, high-reward investment for investors. Personally, I believe there are far better marijuana stocks to place your bets on right now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Here’s Why it’s Not Too Late to Buy Cronos Group Stock

The optimism about U.S. federal marijuana legalization and its anticipation are potent bullish triggers for the Canadian cannabis industry.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now? 

Canopy Growth (TSX:WEED) stock surged by 80% from news out of the U.S., but is enough there without the news…

Read more »

Marijuana plant and cannabis oil bottles isolated
Cannabis Stocks

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030

Quality cannabis stocks such as Green Thumb and Cresco Labs are positioned to deliver outsized gains to shareholders in 2024…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

The Big Mistake I See Cannabis Investors Making Over and Over Again

The news of marijuana slated to be legalized next year has seen a boost for cannabis investors, but they must…

Read more »

cup of cappuccino with a sad face
Cannabis Stocks

A TSX Stock I’d Avoid at All Costs

Despite posting a massive surge in share prices, Canopy Growth (TSX:WEED) is a stock you might be better off steering…

Read more »

edit Jars of marijuana
Cannabis Stocks

4 Reasons Canopy Growth Stock Looks Like a Screaming Buy

Canopy Growth (TSX:WEED) stock has a lot going for it lately, but there are still more hurdles ahead. Even so,…

Read more »